AI-powered agentic platform that automates CT scan analysis for oncologists and radiologists to accelerate tumor characterization and treatment planning.
Cancer diagnosis and treatment initiation in the United States experience significant delays, with patients typically waiting 9 to 11 weeks before therapy begins. These delays contribute substantially to cancer mortality, with each four-week delay increasing relative mortality by approximately 6 to 13 percent.
Cancer diagnosis and treatment initiation in the United States experience significant delays, with patients typically waiting 9 to 11 weeks before therapy begins. These delays contribute substantially to cancer mortality, with each four-week delay increasing relative mortality by approximately 6 to 13 percent.
Nucleo provides an AI-powered agentic platform that automates CT scan analysis, extracting critical oncological metrics such as sarcopenia, body composition assessment, lesion volume, and lesion classification in seconds rather than hours, enabling faster clinical decision-making.
Nucleo provides an AI-powered agentic platform that automates CT scan analysis, extracting critical oncological metrics such as sarcopenia, body composition assessment, lesion volume, and lesion classification in seconds rather than hours, enabling faster clinical decision-making.
Appears active as of Fall 2025 based on Y Combinator backing and recent funding activity.
Event Year: 2025
Appears active as of Fall 2025 based on Y Combinator backing and recent funding activity.
Event Year: 2025
Nucleo is an agentic artificial intelligence platform designed to revolutionize how oncologists and radiologists analyze computed tomography (CT) scans. By automating critical diagnostic and analytical tasks, Nucleo aims to reduce delays in cancer diagnosis and treatment initiation, ultimately improving patient outcomes in oncology care.
Cancer remains a leading cause of mortality globally, but research indicates that a significant portion of cancer deaths result not from the disease itself but from delays in diagnosis and treatment. The median diagnostic interval in the United States is approximately 36 days, while the median time to treatment initiation ranges from 32 to 41 days. This means patients typically wait between 9 and 11 weeks (65 to 80 days) before therapy begins. Studies show that a four-week delay after diagnosis increases relative mortality by 6 to 13 percent, with an additional 8 percent increase for each subsequent four-week delay. These delays represent a critical logistical failure in cancer care delivery.
Nucleo is an agentic artificial intelligence platform designed to revolutionize how oncologists and radiologists analyze computed tomography (CT) scans. By automating critical diagnostic and analytical tasks, Nucleo aims to reduce delays in cancer diagnosis and treatment initiation, ultimately improving patient outcomes in oncology care.
Cancer remains a leading cause of mortality globally, but research indicates that a significant portion of cancer deaths result not from the disease itself but from delays in diagnosis and treatment. The median diagnostic interval in the United States is approximately 36 days, while the median time to treatment initiation ranges from 32 to 41 days. This means patients typically wait between 9 and 11 weeks (65 to 80 days) before therapy begins. Studies show that a four-week delay after diagnosis increases relative mortality by 6 to 13 percent, with an additional 8 percent increase for each subsequent four-week delay. These delays represent a critical logistical failure in cancer care delivery.
Software-as-a-service platform for healthcare institutions
Software-as-a-service platform for healthcare institutions
Oncologists, radiologists, and healthcare institutions providing cancer care
Oncologists, radiologists, and healthcare institutions providing cancer care
Y Combinator backing confirmed Fall 2025; platform actively deployed at major US hospitals.
Hiring: Company is actively hiring; team size of 2 as of 2025.
Y Combinator backing confirmed Fall 2025; platform actively deployed at major US hospitals.
Hiring: Company is actively hiring; team size of 2 as of 2025.
Nucleo addresses these delays by automating key tasks in the oncological workflow. When a physician imports a CT scan into the platform, Nucleo's AI-powered software automatically extracts critical oncological metrics including sarcopenia assessment, body composition analysis, lesion volume measurement, and classification of target versus non-target lesions. This automation enables rapid, consistent analysis that supports tumor characterization and informs treatment strategy selection. By streamlining these essential analytical steps, Nucleo aims to reduce the typical 9 to 11-week diagnostic and treatment initiation period to 10 days or less.
Nucleo addresses these delays by automating key tasks in the oncological workflow. When a physician imports a CT scan into the platform, Nucleo's AI-powered software automatically extracts critical oncological metrics including sarcopenia assessment, body composition analysis, lesion volume measurement, and classification of target versus non-target lesions. This automation enables rapid, consistent analysis that supports tumor characterization and informs treatment strategy selection. By streamlining these essential analytical steps, Nucleo aims to reduce the typical 9 to 11-week diagnostic and treatment initiation period to 10 days or less.
Nucleo's platform leverages advanced machine learning techniques to deliver accurate and rapid analysis of medical imaging data. The technology performs automated body composition analysis and tumor segmentation from medical images, converting complex diagnostic workflows from hours to seconds. The platform is designed to integrate seamlessly into existing clinical workflows, allowing oncologists and radiologists to extract actionable insights without disrupting established processes.
Nucleo's platform leverages advanced machine learning techniques to deliver accurate and rapid analysis of medical imaging data. The technology performs automated body composition analysis and tumor segmentation from medical images, converting complex diagnostic workflows from hours to seconds. The platform is designed to integrate seamlessly into existing clinical workflows, allowing oncologists and radiologists to extract actionable insights without disrupting established processes.
Nucleo's technology has gained traction among leading healthcare institutions across the United States. The platform is currently utilized by Stanford Hospital, Cedars-Sinai, UCI Health, and Weill Cornell, demonstrating clinical validation and adoption by prestigious medical centers. This institutional support indicates confidence in the platform's ability to enhance cancer care delivery and improve clinical decision-making.
Nucleo's technology has gained traction among leading healthcare institutions across the United States. The platform is currently utilized by Stanford Hospital, Cedars-Sinai, UCI Health, and Weill Cornell, demonstrating clinical validation and adoption by prestigious medical centers. This institutional support indicates confidence in the platform's ability to enhance cancer care delivery and improve clinical decision-making.
Nucleo's AI technology streamlines clinical workflows across three critical areas for oncology care. The platform supports tumor characterization by providing detailed metrics and classifications that enhance diagnostic accuracy. It facilitates treatment planning by delivering comprehensive analytical insights that inform therapeutic strategy selection. Additionally, the platform supports clinical trial operations by enabling rapid and consistent analysis of imaging data across patient cohorts.
Nucleo's AI technology streamlines clinical workflows across three critical areas for oncology care. The platform supports tumor characterization by providing detailed metrics and classifications that enhance diagnostic accuracy. It facilitates treatment planning by delivering comprehensive analytical insights that inform therapeutic strategy selection. Additionally, the platform supports clinical trial operations by enabling rapid and consistent analysis of imaging data across patient cohorts.
Nucleo operates as a software-as-a-service platform serving healthcare institutions and oncology practices. The company positions itself as the first agentic platform specifically designed for oncology, addressing a critical gap in clinical workflow automation. By focusing on a specialized medical domain, Nucleo targets institutions seeking to improve diagnostic efficiency and reduce treatment delays.
Nucleo operates as a software-as-a-service platform serving healthcare institutions and oncology practices. The company positions itself as the first agentic platform specifically designed for oncology, addressing a critical gap in clinical workflow automation. By focusing on a specialized medical domain, Nucleo targets institutions seeking to improve diagnostic efficiency and reduce treatment delays.
